Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Selexipag
Drug ID BADD_D02006
Description Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.
Indications and Usage Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
Marketing Status approved
ATC Code B01AC27
DrugBank ID DB11362
KEGG ID D09994
MeSH ID C523468
PubChem ID 9913767
TTD Drug ID D0N2SR
NDC Product Code 66215-718; 66215-602; 66215-612; 47848-060; 70600-007; 66215-606; 66215-616; 66215-610; 66215-614; 70600-029; 66215-628; 66215-604; 66215-608
UNII 5EXC0E384L
Synonyms selexipag | 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide | Uptravi | NS-304 | ACT 293987 | ACT293987 | ACT-293987
Chemical Information
Molecular Formula C26H32N4O4S
CAS Registry Number 475086-01-2
SMILES CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.0020.005634%
Feeling abnormal08.01.09.0140.002969%-
Feeling cold08.01.09.0080.000181%-
Feeling jittery08.01.09.0160.000082%-
Flatulence07.01.04.0020.000543%
Fluid retention14.05.06.002; 20.01.02.0030.002837%-
Flushing08.01.03.025; 23.06.05.003; 24.03.01.0020.002953%
Frequent bowel movements07.02.04.0020.000222%-
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.001127%
Gallbladder disorder09.03.02.0010.000082%-
Gastric cancer07.21.02.001; 16.13.03.0010.000082%-
Gastric haemorrhage07.12.01.001; 24.07.02.0070.000123%
Gastrooesophageal reflux disease07.02.02.0030.000526%
Gastrointestinal disorder07.11.01.0010.001028%-
Generalised oedema08.01.07.004; 14.05.06.0070.000345%
Gingival bleeding07.09.07.001; 24.07.02.0100.000181%-
Haematemesis07.12.02.002; 24.07.02.0110.000082%-
Haematochezia07.12.02.003; 24.07.02.0120.000164%-
Haemoglobin decreased13.01.05.003---
Haemoptysis02.11.04.009; 22.02.03.004; 24.07.01.0060.000123%-
Haemorrhoids07.15.03.001; 24.10.02.0020.000082%
Head discomfort17.02.05.0270.000082%-
Headache17.14.01.0010.025241%
Hepatic cirrhosis09.01.04.0010.000370%-
Hepatic encephalopathy09.01.03.006; 17.13.01.0030.000082%-
Hepatitis09.01.07.0040.000082%-
Hernia08.01.04.0010.000082%-
Hypersomnia17.15.01.001; 19.02.05.0010.000461%
Hyperthyroidism05.02.02.001; 14.11.01.0110.000280%
Hypervolaemia02.05.04.019; 14.05.06.0030.000617%-
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages